Author Archives: Julian Upton

Alfred Hitchcock — Pharma Rep

In 1955, the broadcaster CBS proposed a deal with drugmaker Bristol-Myers (as it was then known) to sponsor a new TV show, Alfred Hitchcock Presents. The show, scheduled to premier later that year, would be a weekly anthology series focused on crime and mystery stories. The unique selling point was that Hitchcock himself was to […]
Posted in Marketing | Tagged , , , , , | Leave a comment

Emerging Pharma Leaders: Ian Harris, Janssen Research & Development

When he left school, Ian Harris wanted a career in brewing. He enrolled on a biochemistry degree with the intention of going on to study a master’s in brewing at Heriot-Watt University in Edinburgh, UK. But after spending, as part of his first degree, a year in the pharmacutical industry developing in vitro disease models for dermatology […]
Posted in leadership, People | Tagged | Leave a comment

EMA Invites Comments on Good Biomarker Practice

The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices. The outcome of the consultation will inform a guideline, which will set criteria to underpin the generation of robust clinical genomic datasets throughout a medicine’s lifecycle,  the choice of genomic techniques and biomarkers, the impact on the relevant study design, and the […]
Posted in Biotech, Europe, Global, Regulatory | Tagged , , | Leave a comment

UK Strengthens Drive to Tackle Dementia

The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made. At the first legacy event of the G8 […]
Posted in Europe, Events, Gene therapy, Global, healthcare | Tagged , , , | Leave a comment

NICE in Conflict-of-Interest Controversy

They say the road to hell is paved with good intentions. The row in the UK over NICE’s call to doctors to increase the use of statins looked to be good example of this handy aphorism. That was until things took a potentially darker turn.
Posted in Europe, healthcare, pricing | Tagged , , , | Leave a comment
  • Categories

  • Meta